Profound Med Corp Stock Price, News & Analysis

Profound Medical Corp (NASDAQ:PROF) has appointed former NFL safety Leonard Wheeler as Global Ambassador for its TULSA-PRO system. Wheeler, who successfully underwent the TULSA procedure for prostate cancer in early 2025, will lead education and awareness initiatives for the company's innovative treatment. The TULSA-PRO system offers an AI-powered, incision-free therapy for prostate conditions, including cancer and BPH, using real-time MR guidance and sound absorption technology. Wheeler, a nine-year NFL veteran turned executive coach and entrepreneur, brings extensive experience in leadership and public speaking through his company Trilucent Global. His personal experience with TULSA-PRO and successful treatment at The Busch Center positions him uniquely to advocate for this alternative to traditional prostate treatments. The partnership aims to expand awareness and adoption of TULSA-PRO among physicians, patients, and private payers through various media channels.

Profound Medical Corp (NASDAQ: PROF) held its Annual General and Special Meeting with strong shareholder participation, as 68.5% of outstanding shares (20,587,011 shares) were represented. All six director nominees were successfully elected to the Board with approval rates ranging from 92.4% to 97%. The highest approval was received by Cynthia Lavoie (97%), while Arthur Rosenthal received the lowest support (92.4%). Shareholders also approved the appointment of PricewaterhouseCoopers LLP as the company's auditor and passed a resolution approving unallocated options under the company's share option plan.

Profound Medical (NASDAQ: PROF) reported strong Q1 2025 financial results, with revenue growing 82% to $2.6 million compared to Q1 2024. The revenue comprised $1.8 million from recurring non-capital revenue and $820,000 from capital equipment sales. Gross margin improved to 71% from 60% year-over-year. The company's TULSA-PRO® treatment data showed diverse patient applications: 82% for prostate cancer, 10% hybrid cases, and 8% salvage cases. However, operating expenses increased to $13.0 million from $8.7 million, leading to a net loss of $10.7 million ($0.36 per share). The company maintained a strong cash position of $46.4 million as of March 31, 2025. Notable developments include positive initial results from the CAPTAIN trial comparing TULSA to robotic radical prostatectomy and new Urology APC Level 7 codes effective 2025.

Profound Medical (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company, announced its upcoming participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference. The company, which specializes in developing customizable, incision-free therapies for diseased tissue ablation, will present a business update on Tuesday, May 6, 2025, at 1:30 p.m. Eastern Time.

The presentation will take place at the Metro Toronto Convention Centre. Investors and interested parties can access the live broadcast and archived recording through the "Webcasts" section under Investors on the company's website at www.profoundmedical.com.

Profound Medical has announced groundbreaking results from their CAPTAIN trial, comparing TULSA procedure with robotic radical prostatectomy (RP) for prostate cancer treatment. The Level 1 study, involving 201 randomized patients across 23 sites, demonstrates significant advantages for TULSA.

Key findings show TULSA patients experienced:

• Zero blood loss compared to 100-200mL for RP
• 0.29 days hospital stay versus 1.24 days for RP
• Significantly lower post-operative pain through day 6
• Higher overall health scores for 30 days post-treatment

TULSA patients showed notably better outcomes in mobility (0% vs 12% extreme problems), self-care (3% vs 17%), and usual activities (17% vs 40%). The study included balanced patient characteristics, with median age ~63 years and similar PSA levels between groups. These results position TULSA as a potentially superior alternative to traditional prostate cancer surgery.

Profound Medical (NASDAQ: PROF; TSX: PRN), a commercial-stage medical device company focused on developing incision-free ablation therapies, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET on the same day, where management will review financial results and discuss business developments from the period. Investors can access the live call through registration and the broadcast will be archived on the company's website under the Investors section.

Profound Medical Corp (NASDAQ:PROF) has announced details for its hybrid investor event scheduled for April 28, 2025, during the AUA Annual Meeting at the Waldorf Astoria in Las Vegas. The 90-minute event, running from 3:30-5:00 PM PT, will feature key presentations from company leadership and medical experts.

The agenda includes:

• Dr. Mathieu Burtnyk presenting CAPTAIN study results comparing TULSA to radical prostatectomy
• Dr. Ram Pathak sharing TULSA-PRO® clinical outcomes
• CEO Dr. Arun Menawat discussing TULSA-AI® for BPH and TULSA+ program with Siemens Healthineers
• Dr. Naveen Kella presenting on TULSA's BPH treatment capabilities
• CCO Tom Tamberrino outlining TULSA+ commercial strategy

The event will conclude with a Q&A session and will be available via webcast on the company's website.

Profound Medical Corp (NASDAQ:PROF; TSX:PRN) has announced a hybrid investor event scheduled for April 28, 2025, during the American Urological Association (AUA) Annual Meeting in Las Vegas. The event will run from 3:30-5:00 PM PT (6:30-8:00 PM ET).

The program will feature presentations from both management and leading physicians, focusing on four key areas:

• TULSA-PRO® technology and its versatility in treating prostate disease patients
• Peri-operative results from the Level 1 CAPTAIN post-market study comparing TULSA procedure to radical prostatectomy
• Introduction of the new TULSA-AI® module for BPH, including a live technology demonstration
• Updates on the TULSA+ program, which integrates TULSA-PRO® with Siemens Healthineers' Magnetom Free.Max interventional MRI

Profound Medical Corp (NASDAQ:PROF) is under investigation by Cohen Milstein Sellers & Toll LLP following significant accounting irregularities. The company, which develops ablation therapies for diseased tissue, disclosed on March 6, 2025, that its Audit Committee discovered a revenue overstatement of $472,000 in Q1 2024.

As a result, Profound's financial statements for the first three quarters of 2024 will require restatement and reissuance. The market reacted negatively to this news, with PROF shares declining 5.9% to close at $6.86 per share on March 7, 2025.